Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trialsFUNAKOSHI, Tomohiro; LATIF, Asma; GALSKY, Matthew D et al.Cancer treatment reviews. 2014, Vol 40, Num 5, pp 636-647, issn 0305-7372, 12 p.Article

Violaceous exanthem as a manifestation of metastatic prostate cancer in skinSLOVIN, Susan F; GALSKY, Matthew D; BUSAM, Klaus et al.Urology (Ridgewood, NJ). 2006, Vol 67, Num 2, pp 420-420, issn 0090-4295, 1 p.Article

Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysisFUNAKOSHI, Tomohiro; LATIF, Asma; GALSKY, Matthew D et al.Cancer treatment reviews. 2013, Vol 39, Num 7, pp 818-830, issn 0305-7372, 13 p.Article

Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate CancerTSAO, Che-Kai; GALSKY, Matthew D; OH, William K et al.European urology. 2014, Vol 66, Num 2, pp 184-185, issn 0302-2838, 2 p.Article

Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-AnalysisSONIA SENG; ZIYUE LIU; GALSKY, Matthew D et al.Journal of clinical oncology. 2012, Vol 30, Num 35, pp 4416-4426, issn 0732-183X, 11 p.Article

Neoadjuvant Therapy Followed by Prostatectomy for Clinically Localized Prostate CancerSONPAVDE, Guru; CHI, Kim N; POWLES, Thomas et al.Cancer. 2007, Vol 110, Num 12, pp 2628-2639, issn 0008-543X, 12 p.Article

Use of Crowdsourcing for Cancer Clinical Trial DevelopmentLEITER, Amanda; SABLINSKI, Tomasz; DIEFENBACH, Michael et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 10, issn 0027-8874, 258.1-258.3Article

Novel agents for muscle-invasive and advanced urothelial cancerSONPAVDE, Guru; ROSS, Robert; POWLES, Thomas et al.BJU international (Papier). 2008, Vol 101, Num 8, pp 937-943, issn 1464-4096, 7 p.Article

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal functionGALSKY, Matthew D; IASONOS, Alexia; MIRONOV, Svetlana et al.Cancer. 2007, Vol 109, Num 3, pp 549-555, issn 0008-543X, 7 p.Article

Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tractGALSKY, Matthew D; IASONOS, Alexia; MIRONOV, Svetlana et al.Urology (Ridgewood, NJ). 2007, Vol 69, Num 2, pp 255-259, issn 0090-4295, 5 p.Article

Metabolic complications with the use of mTOR inhibitors for cancer therapySIVENDRAN, Shanthi; AGARWAL, Neeraj; GARTRELL, Benjamin et al.Cancer treatment reviews. 2014, Vol 40, Num 1, pp 190-196, issn 0305-7372, 7 p.Article

Nomogram for Predicting Survival in Patients With Unresectable and/or Metastatic Urothelial Cancer Who Are Treated With Cisplatin-Based ChemotherapyGALSKY, Matthew D; MOSHIER, Erin; KREGE, Susan et al.Cancer. 2013, Vol 119, Num 16, pp 3012-3019, issn 0008-543X, 8 p.Article

Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 TrialsSONPAVDE, Guru; POND, Gregory R; KO, Yoo-Joung et al.European urology. 2013, Vol 63, Num 4, pp 717-723, issn 0302-2838, 7 p.Article

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate CancerOH, William K; GALSKY, Matthew D; STADLER, Walter M et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 3, pp 626-630, issn 0090-4295, 5 p.Article

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancerSONPAVDE, Guru; APARICIO, Ana M; ASMAR, Lina et al.Urologic oncology. 2011, Vol 29, Num 6, pp 682-689, issn 1078-1439, 8 p.Article

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerGALSKY, Matthew D; SMALL, Eric J; KELLY, W. Kevin et al.Journal of clinical oncology. 2005, Vol 23, Num 7, pp 1439-1446, issn 0732-183X, 8 p.Article

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings : ICUD-EAU International Consultation on Bladder Cancer 2012: Recommendations on Bladder Cancer-Process in a Cancer that Lacks the LimelightSTERNBERG, Cora N; BELLMUNT, Joaquim; VAUGHN, David J et al.European urology. 2013, Vol 63, Num 1, pp 58-66, issn 0302-2838, 9 p.Article

A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder CancerMEEKS, Joshua J; BELLMUNT, Joaquim; STERNBERG, Cora N et al.European urology. 2012, Vol 62, Num 3, pp 523-533, issn 0302-2838, 11 p.Article

Phase 2 Study of Neoadjuvant Docetaxel Plus Bevacizumab in Patients With High-Risk Localized Prostate Cancer: A Prostate Cancer Clinical Trials Consortium TrialROSS, Robert W; GALSKY, Matthew D; TEMPANY, Clare M et al.Cancer. 2012, Vol 118, Num 19, pp 4777-4784, issn 0008-543X, 8 p.Article

The Emerging Role of Circulating Tumor Cell Detection in Genitourinary CancerSMALL, Alexander C; YIXUAN GONG; OH, William K et al.The Journal of urology. 2012, Vol 188, Num 1, pp 21-26, issn 0022-5347, 6 p.Article

Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysisPROVERBS-SINGH, Tracy; CHIU, Sophia K; GALSKY, Matthew D et al.Journal of the National Cancer Institute. 2012, Vol 104, Num 23, pp 1837-1840, issn 0027-8874, 4 p.Article

Treatment of Patients With Metastatic Urothelial Cancer Unfit for Cisplatin-Based ChemotherapyGALSKY, Matthew D; HAHN, Noah M; BELLMUNT, Joaquim et al.Journal of clinical oncology. 2011, Vol 29, Num 17, pp 2432-2438, issn 0732-183X, 7 p.Article

Utility of [¹⁸F]2-Fluoro-2-Deoxyglucose-PET in Sporadic and Tuberous Sclerosis-Associated LymphangioleiomyomatosisYOUNG, Lisa R; FRANZ, David N; NAGARKATTE, Preeti et al.Chest (American College of Chest Physicians). 2009, Vol 136, Num 3, pp 926-933, issn 0012-3692, 8 p.Article

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma : Second-line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapyROSENBERG, Jonathan E; GALSKY, Matthew D; ROHS, Nicholas C et al.Cancer. 2006, Vol 106, Num 1, pp 58-62, issn 0008-543X, 5 p.Article